Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.50 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.50 |
| ▸ | HMGCR known ✓ | P04035 | 1/20 | 0.41 |
| ▸ | NOD2 known ✓ | Q9HC29 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29459574 | 0.87 | LMNA (0.70) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| SCHEMBL480337 | 0.87 | LMNA (0.70) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| SCHEMBL9339940 | 0.86 | MAPT (0.84) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| Water SCHEMBL550437 | 0.86 | LMNA (0.68) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| Sulisobenzone SCHEMBL338882 | 0.83 | LMNA (0.76) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| Sulisobenzone SCHEMBL29378407 | 0.83 | LMNA (0.76) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| Sulisobenzone SCHEMBL28588923 | 0.82 | LMNA (0.74) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| Sulisobenzone SCHEMBL6295947 | 0.81 | LMNA (0.76) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| Sulisobenzone SCHEMBL11277588 | 0.81 | LMNA (0.76) | LMNAMAPTHPGDKDM4EHSD17B10 | |
| Sulisobenzone SCHEMBL10621756 | 0.81 | LMNA (0.76) | LMNAMAPTHPGDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024090506-A1 | HAIR IMPROVING AGENT AND HAIR IMPROVEMENT COMPOSITION | リファインホールディングス株式会社 | 2024-05-02 | — | — | WO | disclosed |
| US-10632089-B2 | Tyrosinase activity inhibitor and external preparation for skin | JO COSMETICS CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| EP-2214625-B1 | EMULSION COMPOSITION | FUJIFILM CORP (JP) | 2018-10-03 | — | — | EP | disclosed |
| US-20180071239-A1 | TYROSINASE ACTIVITY INHIBITOR AND EXTERNAL PREPARATION FOR SKIN | JO COSMETICS CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-1595936-B1 | COMPOSITION FOR EXTERNAL USE | VITAMIN C60 BIORES CORP (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100291008-A1 | EMULSION COMPOSITION | FUJIFILM CORPORATION (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-1364943-B1 | CYSTINE DERIVATIVES AND INHIBITORS FOR THE ACTIVATION OF INFLAMMATORY FACTORS | AJINOMOTO KK (JP) | 2010-10-20 | — | — | EP | disclosed |
| EP-2214625-A1 | EMULSION COMPOSITION | FUJIFILM Corporation (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-2111860-A1 | INFLAMMATION INHIBITOR COMPRISING ZINC SALT OF ACYLAMINO ACID | Ajinomoto Co., Inc. (JP) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009066799-A1 | EMULSION COMPOSITION | FUJIFILM CORPORATION (JP) | 2009-05-28 | — | — | WO | disclosed |
| US-6914075-B2 | Cystine derivative and agent for suppressing activation of inflammatory factors | AJINOMOTO CO., INC. (JP) | 2005-07-05 | — | — | US | disclosed |
| US-20040059110-A1 | Novel cystine derivative and agent for suppressing activation of inflammatory factors | AJINOMOTO CO., INC. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1364943-A1 | NOVEL CYSTINE DERIVATIVES AND INHIBITORS FOR THE ACTIVATION OF INFLAMMATORY FACTORS | Ajinomoto Co., Inc. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-0688559-B1 | Skin anti-ageing composition | SHISEIDO CO LTD (JP) | 2001-06-20 | — | — | EP | disclosed |
| US-6077520-A | ANTI-AGING TOPICAL COMPOSITION INCLUDING AT LEAST ONE OF SULFONYLETHYLENEAMINE OR MERCAPTOSULFONYLETHYLENEAMINE COMPOUNDS OF GIVEN FORMULA AND SPECIFIED ULTRAVIOLET LIGHT PROTECTIVE AGENTS | SHISEIDO COMPANY, LTD. (JP) | 2000-06-20 | — | — | US | disclosed |
| US-5747049-A | AMINOETHYLSULFINIC ACID OR AMINOETHYLTHIOSULFONIC ACID, SUNSCREEN | SHISEIDO COMPANY, LTD. (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0688559-A1 | Skin anti-ageing composition | SHISEIDO COMPANY LIMITED (JP) | 1995-12-27 | — | — | EP | disclosed |
| EP-0349150-B1 | Transparent compostition | SHISEIDO CO LTD (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5162377-A | Cosmetics, Drugs | SHISEIDO COMPANY, LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| EP-0349150-A2 | Transparent compostition | SHISEIDO COMPANY LIMITED (JP) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059110-A1 | Novel cystine derivative and agent for suppressing activation of inflammatory factors | CTH, CBS, CYSLTR1 | PDE4A 1002/4885PDE4D 1137/4885HMGCR 1576/4885 |
| US-10632089-B2 | Tyrosinase activity inhibitor and external preparation for skin | TYR, SOD1, CAT | PDE4A 4561/4885PDE4D 4731/4885HMGCR 1200/4885 |
| US-20180071239-A1 | TYROSINASE ACTIVITY INHIBITOR AND EXTERNAL PREPARATION FOR SKIN | TYR, SOD1, CAT | PDE4A 4561/4885PDE4D 4731/4885HMGCR 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.